Sign In
Buy CYAD
$0.470
+0 (+0%)
At Close: Aug 17, 2023
Celyad Oncology Announces November 2020 Investor Conference Schedule
04:01pm, Monday, 02'nd Nov 2020
MONT-SAINT-GUIBERT, Belgium, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Celyad Oncology Reports Half Year 2020 Financial Results and Second Quarter Business Highlights
08:01pm, Thursday, 06'th Aug 2020
* Interim analysis from alloSHRINK Phase 1 trial demonstrated mPFS of 3.9 months for mCRC patients with MSS disease treated with CYAD-101 following FOLFOX preconditioning; expansion cohort of alloSHRI
Celyad Oncology to Announce First Half 2020 Financial Results and Host Conference Call
05:00am, Monday, 03'rd Aug 2020
Regulatory News:
Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate
02:34pm, Wednesday, 15'th Jul 2020
Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.
Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy
05:00am, Tuesday, 14'th Jul 2020
Regulatory News:
Celyad Rebrands as Celyad Oncology
05:00am, Wednesday, 10'th Jun 2020
MONT-SAINT-GUIBERT, Belgium, June 10, 2020 (GLOBE NEWSWIRE) -- Celyad SA (Euronext & Nasdaq: CYAD), clinical-stage biotechnology company focused on the discovery and development of chimeric antigen
First-in-class TIM-based non-gene edited allogeneic CAR-T candidate, CYAD-101, shows encouraging clinical activity with no evidence of graft-versus-host disease in.
5 Health Care Stocks to Bet on as Coronavirus Woes Linger
01:34pm, Wednesday, 27'th May 2020
The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.
Celyad Announces June 2020 Conference Schedule
05:00am, Tuesday, 26'th May 2020
MONT-SAINT-GUIBERT, Belgium, May 26, 2020 -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of.
All You Need to Know About Celyad SA (CYAD) Rating Upgrade to Strong Buy
04:00pm, Monday, 25'th May 2020
Celyad SA (CYAD) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 “Strong Buy” Healthcare Stocks That Could Double in the Next Year
11:00am, Sunday, 24'th May 2020
Out on Wall Street, stocks were able to pull out a major win. Despite being a more volatile week of trading, the three major U.S. stock indexes were each able to notch a more than 3% weekly-gain, with
Celyad Announces First Quarter 2020 Financial Results and Recent Business Highlights
05:00am, Thursday, 07'th May 2020
MONT-SAINT-GUIBERT, Belgium, May 07, 2020 -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of.
Celyad Appoints Seasoned Industry Executives to Board of Directors
05:00am, Wednesday, 06'th May 2020
MONT-SAINT-GUIBERT, Belgium, May 06, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T c
Two accepted abstracts will be presented virtually in a prerecorded poster presentation MONT-SAINT-GUIBERT, Belgium, April 30, 2020 -- Celyad (Euronext Brussels and Paris, and.
Celyad to Host Remote 2020 Ordinary General Meeting
05:00am, Wednesday, 22'nd Apr 2020
MONT-SAINT-GUIBERT, Belgium, April 22, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T
